Fresenius Medical Care Q2 Adjusted EPADS $0.32 Beats $0.24 Estimate, Sales $5.26B Beat $5.19B Estimate
Portfolio Pulse from Benzinga Newsdesk
Fresenius Medical Care reported Q2 earnings of $0.32 per share, beating the analyst consensus estimate of $0.24 by 33.33%. The company's quarterly sales of $5.26 billion also surpassed the analyst consensus estimate of $5.19 billion by 1.33%. However, this represents a 21.95% decrease in earnings and a 3.73% increase in sales compared to the same period last year.
August 04, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fresenius Medical Care's Q2 earnings and sales exceeded analyst estimates, which could positively impact the company's stock in the short term.
Fresenius Medical Care's better-than-expected Q2 results could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100